BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29641738)

  • 1. Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.
    Súss SKA; Mesa CO; Carvalho GA; Miasaki FY; Chaves CP; Fuser DC; Corbo R; Momesso D; Bulzico DA; Graf H; Vaisman F
    Arch Endocrinol Metab; 2018; 62(2):149-156. PubMed ID: 29641738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
    Park SY; Kim HI; Choi JY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn SH; Kim K; Jeong JG; Kim SW; Chung JH; Kim TH
    Oral Oncol; 2018 Sep; 84():41-45. PubMed ID: 30115474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.
    Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP
    Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Important is the Timing of Radioiodine Ablation in Differentiated Thyroidal Carcinomas: A Referral Centre Experience.
    Simsek FS; Balci TA; Donder Y; Ugur K; Kilinc F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(3):157-162. PubMed ID: 31982352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
    Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
    Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
    Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine remnant ablation: current indications and dosing regimens.
    Haugen BR
    Endocr Pract; 2012; 18(4):604-10. PubMed ID: 22849876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
    Forleo R; Fralassi N; Maino F; Capezzone M; Brilli L; Pilli T; Cantara S; Castagna MG
    J Endocrinol Invest; 2021 Jan; 44(1):139-144. PubMed ID: 32388842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.
    Kawabe J; Higashiyama S; Kotani K; Yoshida A; Onoda N; Shiomi S
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):68-75. PubMed ID: 27125316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment.
    Abelleira E; Peñaloza MA; Jerkovich F; Bueno F; Pitoia F
    Arch Endocrinol Metab; 2021 Nov; 65(3):315-321. PubMed ID: 34731559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
    Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
    Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.